The ARUBA TrialARUBA is designed to determine whether symptom management with medicines improves long-term outcomes of patients with unruptured brain arteriovenous malformations (AVM’s) compared to interventional therapy, such as surgery, to remove the AVM. Patients are randomized to receive either medical management of any symptoms related to the AVM, or to receive an intervention. This study is open to patients over the age of 18 who have a known brain arteriovenous malformation, who have never undergone a procedure to treat the AVM, and who have never had any bleeding from the AVM. Patients must be willing to be followed in the study for a minimum of 5 years.
IRIS TrialIRIS tests a common medication, ACTOS®, for its effectiveness in preventing recurrent strokes in patients who have insulin resistance. A fasting blood test is needed to determine if a patient has this condition. The study is open to people over the age of 45, who have had a stroke in the past 6 months, are insulin resistant, and are not diabetic. Patients will be put into one of two groups. One group will receive placebo, and the other will receive medication. Patients must be willing to remain in the study for approximately 3 years.
POINT Clinical TrialPOINT: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke. The objective is to determine whether clopidogrel 75 mg per day for 89 days, after a loading dose of clopidogrel 600 mg, with aspirin, can prevent major ischemic vascular events (stroke, heart attack). This is a randomized, double-blind trial. Patients will be randomized into one of two treatment groups: clopidogrel and aspirin or placebo and aspirin. The trial will be offered to patients who are 18 years of age or older and have been diagnosed with a TIA or a minor stroke and can begin treatment within 12 hours of the onset of symptoms. There are other medical criteria that must be met. Patients will be followed for 90 days. This trial is sponsored by The National Institute of Neurological Disorders and Stroke (NINDS), and the University of California San Francisco.
CLEAR-IICLEAR III is designed to compare 2 treatments for bleeding in the brain, to see which one has better results. Patients will be randomized to one of the 2 treatment groups. One group will have rt-PA (the “clot-busting” drug) administered directly into the brain by a small tube; the other group will have a placebo (a fluid that doesn’t contain any medicine) administered the same way. This study is open to patients age 18 to 80, who have been diagnosed with bleeding in 2 of the ventricles in the brain, and who meet other medical criteria. Patients in the study will be followed for 12 months. This study is sponsored by the National Institute of Neurological Disorders and Johns Hopkins University.

MISTIEMISTIE: The purpose of this trial is to determine the best method of removing a clot from the brain. Patients will either have surgery to remove the clot, or they will receive rt-PA (the “clot-buster” drug) administered directly into the clot through a small tube placed in the brain. This study is open to patients age 18 to 80, who have a diagnosis of sudden bleeding in the brain, and who meet other medical criteria. Patients in the study will be followed for 12 months. This study is sponsored by the National Institute of Neurological Disorders and Johns Hopkins University.
STICH II: This study is designed to compare treatments for bleeding in the brain. Patients will either have surgery very soon after the bleeding is diagnosed, or they will have surgery after a period of conservative treatment. This study is open to patients who are age 20 and over, and who have a diagnosis of bleeding in the brain, who meet other medical criteria, and who are being treated by a neurosurgeon whose opinion is that either treatment would benefit the patient. Patients in the study will be followed for 12 months. This study is sponsored by Newcastle General Hospital in the United Kingdom.
 

(top)